These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34524199)

  • 21. Ribotyping of Clostridioides difficile in the Liberec Regional Hospital: a tertiary health care facility.
    Kracík M; Dolinová I; Žemličková H
    Folia Microbiol (Praha); 2023 Apr; 68(2):315-320. PubMed ID: 36454512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samples.
    van Rossen TM; van Prehn J; Koek A; Jonges M; van Houdt R; van Mansfeld R; Kuijper EJ; Vandenbroucke-Grauls CMJE; Budding AE
    Antimicrob Resist Infect Control; 2021 Jan; 10(1):23. PubMed ID: 33514422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining the Extent of Contamination, Antibiotic Resistance, and Genetic Diversity of
    Ansarian Barezi A; Shakerian A; Rahimi E; Esfandiari Z
    Biomed Res Int; 2023; 2023():3524091. PubMed ID: 37101693
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples.
    Darkoh C; Dupont HL; Kaplan HB
    J Clin Microbiol; 2011 Dec; 49(12):4219-24. PubMed ID: 21976761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predominance of Clostridioides difficile PCR ribotype 181 in northern Greece, 2016-2019.
    Kachrimanidou M; Metallidis S; Tsachouridou O; Harmanus C; Lola V; Protonotariou E; Skoura L; Kuijper E
    Anaerobe; 2022 Aug; 76():102601. PubMed ID: 35688364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multicenter Study of the Revogene C. difficile System for Detection of the Toxin B Gene from Unformed Stool Specimens.
    Mashock MJ; Faron ML; Carroll KC; Dang C; Lewis S; Salimnia H; Lephart P; Loo VG; Schmitt BH; Young S; Buchan BW; Ledeboer NA
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31776191
    [No Abstract]   [Full Text] [Related]  

  • 27. Low-toxin
    Anwar F; Roxas BAP; Shehab KW; Ampel NM; Viswanathan VK; Vedantam G
    Emerg Microbes Infect; 2022 Dec; 11(1):1982-1993. PubMed ID: 35880487
    [No Abstract]   [Full Text] [Related]  

  • 28. Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology.
    Sandlund J; Bartolome A; Almazan A; Tam S; Biscocho S; Abusali S; Bishop JJ; Nolan N; Estis J; Todd J; Young S; Senchyna F; Banaei N
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30158195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-genome sequencing of clinical Clostridioides difficile isolates reveals molecular epidemiology and discrepancies with conventional laboratory diagnostic testing.
    McLean K; Balada-Llasat JM; Waalkes A; Pancholi P; Salipante SJ
    J Hosp Infect; 2021 Feb; 108():64-71. PubMed ID: 33227298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the introduction of nucleic acid amplification testing on Clostridioides difficile detection and ribotype distribution in Wales.
    Perry MD; White PL; Morris TE
    Anaerobe; 2021 Feb; 67():102313. PubMed ID: 33309680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes.
    Yepez Guevara EA; Aitken SL; Olvera AV; Carlin L; Fernandes KE; Bhatti MM; Garey KW; Adachi J; Okhuysen PC
    Clin Infect Dis; 2021 May; 72(10):e460-e465. PubMed ID: 32803229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performances of the BD MAX™ CDIFF assay for the detection of toxigenic Clostridioides difficile using Cary-Blair preserved samples.
    Anne-Gaëlle R; Célia S; Jeanne C; Frédéric B; Anne T; Coralie B; Kevin S; Sonia F; Pascaline D; Francois V; Olivier D; Fréderic L
    Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115701. PubMed ID: 35596982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of C. difficile toxin as a model assay for performing fully automated high-throughput RT-PCR on clinical stool samples.
    Eigner U; Nörz D; Reucher S; Furrer J; Sun J; Chu K; Kolb M; Hefner N; Pfefferle S; Lütgehetmann M
    J Microbiol Methods; 2020 May; 172():105882. PubMed ID: 32119956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Evaluation of the Performance of C. Diff Quik Chek Complete and Toxin A + B (Clostridium difficile) DUO Diagnostic Tests Compared with Toxigenic Culture in the Diagnosis of Clostridium difficile Infection.
    Yazisiz H; Özyurt ÖK; Öngüt G; Baysan BÖ; Dönmez L; Günseren F; Çolak D; Öğünç D
    Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota in burned patients with Clostridioides difficile infection.
    Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
    Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MALDI-TOF MS: An alternative approach for ribotyping Clostridioides difficile isolates in Brazil.
    Carneiro LG; Pinto TCA; Moura H; Barr J; Domingues RMCP; Ferreira EO
    Anaerobe; 2021 Jun; 69():102351. PubMed ID: 33621659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Clostridioides difficile toxin B gene in clinical stool specimens using rapid diagnostic quenching probe-polymerase chain reaction assay.
    Hara Y; Nakamura K; Tanno D; Toyokawa M; Suzuki H; Ohashi K; Harada R; Hidaka T; Nagano T; Torii K; Kanemitsu K
    J Microbiol Methods; 2023 Feb; 205():106666. PubMed ID: 36608708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of a newly developed high-speed polymerase chain reaction analysis system for the diagnosis of Clostridioides difficile infection.
    Furukawa K; Mitsutake H; Aso R; Sekizawa R; Okanda T; Hayashi K; Matsumoto T; Nakamura S
    J Infect Chemother; 2021 May; 27(5):715-721. PubMed ID: 33402305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Healthcare Facility-Onset Clostridioides difficile Infection and the Impact of Testing Schemes in an Acute Care Hospital System in New York City, 2016-2019.
    Episcopia B; Gupta A; Fornek M; Kaminski M; Malik S; Sunny S; Landman D; Xavier G; Quale J
    Am J Infect Control; 2021 Oct; 49(10):1262-1266. PubMed ID: 33716096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection.
    Alonso CD; Pollock NR; Garey KW; Gonzales-Luna AJ; Williams DN; Daugherty K; Cuddemi C; Villafuerte-Gálvez J; White NC; Chen X; Xu H; Sprague R; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Kelly CP
    Clin Infect Dis; 2022 Nov; 75(11):2019-2022. PubMed ID: 35607815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.